Man Group
STOK icon

Man Group’s Stoke Therapeutics STOK Stock Holding History

Man Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,361
Closed -$80.8K – 2275
2023
Q4 		$80.8K Buy
+15,361
New +$65.7K ﹤0.01% 1996
2023
Q3 		– Sell
-96,554
Closed -$635K – 1536
2023
Q2 		$1.03M Buy
+96,554
New +$1.03M ﹤0.01% 1381
2023
Q1 		– Hold
0
– – – 1383
2022
Q4 		– Sell
-62,939
Closed -$808K – 2206
2022
Q3 		$808K Buy
+62,939
New +$1M ﹤0.01% 1363

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group's STOK Position: Q1 2024 in Review

Man Group sold out of Stoke Therapeutics (STOK) in Q1 2024, closing a stake of 15,361 shares — an estimated $80.8K sold.

Man Group first reported a position in STOK in Q3 2022 and held it in 3 quarters. The position peaked at $1.03M in Q2 2023. 103 funds tracked by Wall St. Rank hold STOK as of Q1 2024.

  • Man Group reported no remaining Stoke Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Man Group sold 15,361 Stoke Therapeutics shares in Q1 2024, an estimated $80.8K.
  • Man Group first reported a position in Stoke Therapeutics in Q3 2022 and held it in 3 quarters.
  • Man Group's Stoke Therapeutics position peaked at $1.03M in Q2 2023.
  • 103 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.